勃起功能障碍药物市场规模、份额、成长分析（按类型、给药途径和地区）- 产业预测，2024-2031 年

Erectile Dysfunction Drugs Market Size, Share, Growth Analysis, By Type (Viagra, Cialis), By Route of Administration (Oral Mode of Administration, Injectable Mode of Administration), By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年，勃起功能障碍药物的全球市场规模为24亿美元，从2023年的26.2亿美元增长到2031年的53亿美元，在预测期内（2024-2031年）预计将以复合年增长率增长。

由于几个相互关联的因素，勃起功能障碍药物的全球市场正在显着成长。肥胖、心血管疾病、糖尿病和高血压等与文明病的流行，以及久坐生活方式的增加，导致对这些药物的需求增加。此外，随着患者对勃起功能障碍认识的提高，老年人口的不断增长也增加了对有效治疗方案的需求。新兴市场的政府措施和公共卫生宣传活动正在进一步支持市场扩张。替代学名药的存在以及相关的生活方式压力也正在增加市场活力。此外，越来越多的男性出现勃起功能障碍，以及关键药物专利的到期，都证明了有利的市场条件。对研发的投资以及专注于创新治疗的临床试验正在创造强劲的成长机会。然而，市场面临着患者依从性差、假药盛行以及可能阻碍进展的潜在副作用等挑战。随着市场的发展，相关人员必须解决这些障碍，同时利用成长动力来有效驾驭复杂的勃起功能障碍药物市场。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Hims, Inc.（US）
Sildenafil Therapeutics LLC（US）
Eli Lilly and Company（US）
MediSprout（US）
NantKwest, Inc.（US）
Cipla Limited（India）
Apexigen, Inc.（US）
NantWorks LLC（US）
Sorrento Therapeutics, Inc.（US）
Tetra Bio-Pharma Inc.（Canada）
Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Hims, Inc.（US）
Sildenafil Therapeutics LLC（US）
Eli Lilly and Company（US）
MediSprout（US）
NantKwest, Inc.（US）
Cipla Limited（India）
Apexigen, Inc.（US）
NantWorks LLC（US）
Sorrento Therapeutics, Inc.（US）
Tetra Bio-Pharma Inc.（Canada）

简介目录

Product Code: SQMIG35I2259

Global Erectile Dysfunction Drugs Market size was valued at USD 2.4 billion in 2022 and is poised to grow from USD 2.62 billion in 2023 to USD 5.3 billion by 2031, growing at a CAGR of 9.20% during the forecast period (2024-2031).

The global market for erectile dysfunction drugs is witnessing significant growth driven by several interconnected factors. The rise in sedentary lifestyles, alongside the prevalence of lifestyle-related conditions such as obesity, cardiovascular diseases, diabetes, and hypertension, is leading to a higher demand for these medications. Additionally, the growing geriatric population is amplifying the need for effective treatment options, supported by increased patient awareness around erectile dysfunction. Government initiatives and public health campaigns in developing regions are further propelling market expansion. The presence of generic drug alternatives and associated lifestyle stresses are enhancing market dynamics as well. Furthermore, an increasing number of men experiencing erectile dysfunction, coupled with the expiration of patents for major drugs, is proving advantageous for the market landscape. Investment in research and development, along with clinical trials focusing on innovative treatments, is creating robust growth opportunities. However, the market faces challenges such as poor patient adherence, the prevalence of counterfeit medications, and potential adverse effects that may impede progress. As the market evolves, addressing these hurdles while capitalizing on growth drivers will be crucial for stakeholders to navigate the complexities of the erectile dysfunction drug market effectively.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Erectile Dysfunction Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Erectile Dysfunction Drugs Market Segmental Analysis

Global Erectile Dysfunction Drugs Market is segmented by Type, Route of Administration, and region. Based on Type, the market is segmented into Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), and Other Drugs. Based on Route of Administration, the market is segmented into Oral Mode of Administration, Injectable Mode of Administration, and Other Modes of Administration. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Erectile Dysfunction Drugs Market

The escalating prevalence of erectile dysfunction (ED) worldwide significantly propels the Global Erectile Dysfunction Drugs market, driven by a confluence of factors including sedentary lifestyles, obesity, and age-related changes. Chronic health conditions such as diabetes and cardiovascular diseases further exacerbate this issue, leading to a higher demand for effective treatment options. As societal awareness surrounding men's health increases and stigma surrounding ED diminishes, more individuals are seeking medical interventions. This trend is further supported by ongoing innovations in pharmaceutical therapies, bolstering the market's growth as a rising number of patients turn to prescribed medications and over-the-counter solutions to enhance their sexual health and overall quality of life.

Restraints in the Global Erectile Dysfunction Drugs Market

One significant market restraint for the global erectile dysfunction drugs market is the rigorous regulatory landscape governing drug development and approval. The process involves extensive clinical trials and stringent post-marketing surveillance requirements, which are both time-consuming and costly for manufacturers. These regulatory hurdles can delay product launches and increase the overall investment needed for bringing new drugs to market. Consequently, the complexity and duration of the approval process may deter potential entrants and limit innovation within the sector, ultimately constraining market growth and reducing the availability of novel treatment options for consumers seeking effective erectile dysfunction solutions.

Market Trends of the Global Erectile Dysfunction Drugs Market

The Global Erectile Dysfunction Drugs market is experiencing a notable shift towards non-oral administration routes, driven by an evolving consumer preference for treatment options that enhance convenience and immediacy. As traditional oral medications, particularly PDE5 inhibitors, continue to dominate the landscape, there is a marked rise in interest for alternative methods such as topical creams, injections, and transdermal patches. These innovative delivery systems provide localized treatment, potentially reducing systemic side effects and improving efficacy. This trend reflects a broader movement towards personalized medicine, catering to diverse patient needs and preferences, thereby fostering growth opportunities within the market.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Ecosystem of the Market
Case study Analysis
PESTEL Analysis
Regulatory Landscape
Top Investment Analysis
Key Success Factor
Degree of Competition

Erectile Dysfunction Drugs Market by Product

Market Overview
Viagra (sildenafil citrate)
Cialis (Tadalafil)
Levitra/Staxyn (vardenafil)
Stendra/Spedra (avanafil)
Zydena (udenafil)
Other Drugs

Erectile Dysfunction Drugs Market by Route of Administration

Market Overview
Oral Mode of Administration
Injectable Mode of Administration
Other Modes of Administration

Erectile Dysfunction Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hims, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sildenafil Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediSprout (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apexigen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantWorks LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetra Bio-Pharma Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hims, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sildenafil Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediSprout (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apexigen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantWorks LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetra Bio-Pharma Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments